皮肤性

订阅

MedSci主页 / 所有栏目 / 皮肤性

JAMA Dermat：利妥昔单抗治疗顽固性疱疹样皮炎

2017-01-22 MedSci MedSci原创

利妥昔单抗疱疹样皮炎
关注

疱疹样皮炎（DH）是在腹腔疾病的背景下出现的自身免疫性起泡性病症。虽然通常由无麸质饮食和氨苯砜管理，但是难治性DH的标准治疗方案尚未统一定义。近期，一项发表在JAMA Dermat杂志上的文章报道了根据淋巴瘤方案（4次每周输注375mg / m 2）所研究的未由不含麸质饮食（具有较差的粘附性）、氨苯砜和常规免疫抑制剂控制的年龄为80岁的DH患者对利妥昔单抗治疗的反应。治疗后的十三个月，患者的瘙痒和

疱疹样皮炎（DH）是在腹腔疾病的背景下出现的自身免疫性起泡性病症。虽然通常由无麸质饮食和氨苯砜管理，但是难治性DH的标准治疗方案尚未统一定义。

近期，一项发表在JAMA Dermat杂志上的文章报道了根据淋巴瘤方案（4次每周输注375mg / m 2）所研究的未由不含麸质饮食（具有较差的粘附性）、氨苯砜和常规免疫抑制剂控制的年龄为80岁的DH患者对利妥昔单抗治疗的反应。

治疗后的十三个月，患者的瘙痒和疾病的临床表现完全消退，针对表皮和组织的转谷氨酰胺酶的抗体的正常。此患者获得了完全的临床和血清学缓解，并且在治疗后长达18个月保持无症状。

这项病例报道介绍了用利妥昔单抗治疗的第一例DH患者，此患者获得了完全的临床和血清学缓解。研究者建议利妥昔单抗可以作为顽固性DH的可行治疗选择。

原始出处：
Albers LN, Zone JJ, Stoff BK, Feldman RJ.Rituximab Treatment for Recalcitrant Dermatitis Herpetiformis.JAMA Dermatol. 2016 Dec 28. doi: 10.1001/jamadermatol.2016.4676.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660397, encodeId=7f2d166039e1f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Feb 06 18:27:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632865, encodeId=bb86163286507, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Jun 04 22:27:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175639, encodeId=09ae1e5639dc, content=只有治疗了一例……, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRhMvhh5icA01VlaGzCZQ0VOzgHK4JVfic4aufJ9ic3NibwHq6QCpLFptGLWLOyZms63YicPa1vgcuVlT2/0, createdBy=b3172018021, createdName=Dr.赵, createdTime=Sat Feb 11 22:21:56 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172359, encodeId=1df81e235996, content=赞一个，小编辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jan 24 13:05:31 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580380, encodeId=c2a2158038093, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Tue Jan 24 04:27:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-02-06 花花1374

    #利妥昔#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1660397, encodeId=7f2d166039e1f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Feb 06 18:27:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632865, encodeId=bb86163286507, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Jun 04 22:27:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175639, encodeId=09ae1e5639dc, content=只有治疗了一例……, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRhMvhh5icA01VlaGzCZQ0VOzgHK4JVfic4aufJ9ic3NibwHq6QCpLFptGLWLOyZms63YicPa1vgcuVlT2/0, createdBy=b3172018021, createdName=Dr.赵, createdTime=Sat Feb 11 22:21:56 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172359, encodeId=1df81e235996, content=赞一个，小编辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jan 24 13:05:31 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580380, encodeId=c2a2158038093, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Tue Jan 24 04:27:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-06-04 limedical1981

    #顽固性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1660397, encodeId=7f2d166039e1f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Feb 06 18:27:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632865, encodeId=bb86163286507, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Jun 04 22:27:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175639, encodeId=09ae1e5639dc, content=只有治疗了一例……, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRhMvhh5icA01VlaGzCZQ0VOzgHK4JVfic4aufJ9ic3NibwHq6QCpLFptGLWLOyZms63YicPa1vgcuVlT2/0, createdBy=b3172018021, createdName=Dr.赵, createdTime=Sat Feb 11 22:21:56 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172359, encodeId=1df81e235996, content=赞一个，小编辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jan 24 13:05:31 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580380, encodeId=c2a2158038093, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Tue Jan 24 04:27:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-02-11 Dr.赵

    只有治疗了一例……

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1660397, encodeId=7f2d166039e1f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Feb 06 18:27:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632865, encodeId=bb86163286507, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Jun 04 22:27:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175639, encodeId=09ae1e5639dc, content=只有治疗了一例……, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRhMvhh5icA01VlaGzCZQ0VOzgHK4JVfic4aufJ9ic3NibwHq6QCpLFptGLWLOyZms63YicPa1vgcuVlT2/0, createdBy=b3172018021, createdName=Dr.赵, createdTime=Sat Feb 11 22:21:56 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172359, encodeId=1df81e235996, content=赞一个，小编辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jan 24 13:05:31 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580380, encodeId=c2a2158038093, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Tue Jan 24 04:27:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-01-24 虈亣靌

    赞一个，小编辛苦了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1660397, encodeId=7f2d166039e1f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Feb 06 18:27:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632865, encodeId=bb86163286507, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Jun 04 22:27:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175639, encodeId=09ae1e5639dc, content=只有治疗了一例……, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRhMvhh5icA01VlaGzCZQ0VOzgHK4JVfic4aufJ9ic3NibwHq6QCpLFptGLWLOyZms63YicPa1vgcuVlT2/0, createdBy=b3172018021, createdName=Dr.赵, createdTime=Sat Feb 11 22:21:56 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172359, encodeId=1df81e235996, content=赞一个，小编辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jan 24 13:05:31 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580380, encodeId=c2a2158038093, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Tue Jan 24 04:27:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-01-24 ms2694732865965676

    #疱疹#

    0

相关资讯

Lancet：利妥昔单抗加化疗治疗伯基特淋巴瘤成人患者效果较好

短期强化化疗是伯基特白血病或淋巴瘤成人患者的护理标准。单组的研究结果表明，将利妥昔单抗加入到这些治疗方案中可以改善患者的预后。该研究目的是在一项随机试验中测试这种可能性。原始出处：Vincent Ribrag,Serge Koscielny, Jacques Bosq,et al.Rituximab and dose-dense chemotherapy for adults with Burki

NEJM：利妥昔单抗可延长B细胞急性淋巴细胞白血病患者生存期

利妥昔单抗治疗可改善非霍奇金淋巴瘤患者的预后。B细胞急性淋巴细胞白血病（ALL）也具有CD20抗原，利妥昔单抗可以靶向CD20抗原。虽然单组研究已经表明，将利妥昔单抗添加到化疗中可以改善此类患者的预后，但这个假设还尚未在随机试验中进行测试。

2016CCO实践指南：利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病发布

利妥昔单抗是FDA批准用于癌症治疗的第一个单克隆抗体，主要应用于非霍奇金淋巴瘤包括慢性淋巴细胞白血病的治疗。本文主要针对利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病的合理用药提供共识指南。全文获取：下载地址：指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Lancet：类风湿性关节炎生物制剂初始治疗：利妥昔单抗or TNF抑制剂？

生物制剂的出现掀开了风湿病治疗的新篇章。但肿瘤坏死因子（TNF）抑制剂和耗竭B细胞的药物对于活动性类风湿性关节炎孰优孰劣，尚未比较。2016年7月，发表在《Lancet》的一项开放式标签、随机对照、非劣效性试验对二者的安全性、有效性和成本效果进行了比较。肿瘤坏死因子（TNF）抑制剂和耗竭B细胞的药物对于活动性类风湿性关节炎均有非常好的效果，但至今没有随机对照试验直接比较其安全性、有效性和成本效果。

J Rheumatol：利妥昔单抗治疗RA后乙肝病毒再活化的风险很低

J Rheumatol：利妥昔单抗治疗RA后乙肝病毒再活化的风险很低据发表于对于J Rheumatol 的一项新的研究报道显示，对于曾患有乙型现已治愈的类风湿性关节炎患者来说，使用利妥昔单抗联合疾病修饰型抗风湿病药物治疗后乙型肝炎病毒再活化的风险很低。研究共纳入了33名乙肝表面抗原阴性/抗乙型肝炎核心抗原阳性的来风湿性关节炎患者。在为期34个月的治疗中，研究人员给予这些患者3个周期的利妥昔单抗联合

Lancet：利妥昔单抗治疗类风湿关节炎患者优于TNF抑制剂

肿瘤坏死因子（TNF）抑制和B细胞耗竭是活动性类风湿性关节炎非常有效的治疗方法，但至今没有随机对照试验直接比较其安全性，有效性和成本效益。本研究是为了检验，使用利妥昔单抗与TNF抑制剂治疗未经生物治疗的类风湿关节炎患者相比，有临床上非劣效性，费用也会更低的假设。原始出处：Duncan Porter,Jurgen van Melckebeke,James Dale,et al.Tumour necr